Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Eyenovia Inc (EYEN)

Eyenovia Inc (EYEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,650
  • Shares Outstanding, K 47,386
  • Annual Sales, $ 4 K
  • Annual Income, $ -27,260 K
  • 60-Month Beta 1.64
  • Price/Sales 6,322.35
  • Price/Cash Flow N/A
  • Price/Book 2.53
Trade EYEN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.67
  • Most Recent Earnings $-0.18 on 03/18/24
  • Latest Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 408.61% ( -167.86%)
  • Historical Volatility 144.87%
  • IV Percentile 88%
  • IV Rank 46.77%
  • IV High 824.51% on 11/16/23
  • IV Low 43.19% on 06/12/23
  • Put/Call Vol Ratio 0.23
  • Today's Volume 58
  • Volume Avg (30-Day) 119
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 5,595
  • Open Int (30-Day) 6,343

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.25
  • Number of Estimates 3
  • High Estimate -0.18
  • Low Estimate -0.38
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5010 +41.98%
on 04/10/24
1.1900 -40.23%
on 03/26/24
-0.4687 (-39.72%)
since 03/25/24
3-Month
0.5010 +41.98%
on 04/10/24
2.5700 -72.32%
on 03/04/24
-0.8687 (-54.98%)
since 01/25/24
52-Week
0.5010 +41.98%
on 04/10/24
5.8500 -87.84%
on 05/03/23
-3.7987 (-84.23%)
since 04/25/23

Most Recent Stories

More News
Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery

/PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into a licensing agreement with...

EYEN : 0.7113 (+21.90%)
Eyenovia Expands Its US Manufacturing Capabilities

Eyenovia is stepping up the capabilities of its facilities and taking advantage of the thriving innovation culture and expertise in Reno, Nevada, and Redwood City, California

EYEN : 0.7113 (+21.90%)
Glancy Prongay & Murray LLP Announces Investigation of Eyenovia, Inc. (EYEN)

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Eyenovia, Inc. (Nasdaq: EYEN) concerning the Company and its directors’ and officers’ possible violations of state laws.

EYEN : 0.7113 (+21.90%)
Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

/PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into a collaboration agreement with...

EYEN : 0.7113 (+21.90%)
Eyenovia Reports Second Quarter 2022 Financial Results

Announced appointment of Michael Rowe as Chief Executive Officer and Board member Mydcombi™ NDA resubmission on track for the fourth quarter of 2022 ...

EYEN : 0.7113 (+21.90%)
Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Tops Revenue Estimates

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -28.57% and 34.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

SYRS : 5.10 (+0.59%)
EYEN : 0.7113 (+21.90%)
ProQR (PRQR) Reports Q2 Loss, Lags Revenue Estimates

ProQR (PRQR) delivered earnings and revenue surprises of 15.38% and 9.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

PRQR : 1.96 (-2.49%)
EYEN : 0.7113 (+21.90%)
Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member

Appointment of Mr. Rowe, Eyenovia’s current Chief Operating Officer, maintains continuity while bringing significant ophthalmic industry, operations and...

EYEN : 0.7113 (+21.90%)
Eyenovia Provides Manufacturing Update and Announces Appointment of Bren Kern as SVP of Manufacturing and Operations

New internal manufacturing capabilities to complement existing contract manufacturing relationships...

EYEN : 0.7113 (+21.90%)
Eyenovia Strategic Partner Arctic Vision Enrolls First Patient in Phase III Clinical Trial of ARVN003 (MicroLine) for Presbyopia in China

Arctic Vision also licensed and is developing Eyenovia’s programs for pediatric progressive myopia (MicroPine) and pharmacologic mydriasis (MydCombi™) in...

EYEN : 0.7113 (+21.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eyenovia, Inc. is a clinical stage biopharmaceutical company which engages in developing therapeutics for the treatment of prominent eye diseases primarily in the United States. Its product portfolio includes MicroProst, MicroStat, MicroTears and MicroPine which are in clinical stage. Eyenovia, Inc....

See More

Key Turning Points

3rd Resistance Point 1.1151
2nd Resistance Point 0.9663
1st Resistance Point 0.8388
Last Price 0.7113
1st Support Level 0.5625
2nd Support Level 0.4137
3rd Support Level 0.2862

See More

52-Week High 5.8500
Fibonacci 61.8% 3.8067
Fibonacci 50% 3.1755
Fibonacci 38.2% 2.5443
Last Price 0.7113
52-Week Low 0.5010

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar